Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
The Oncotrail RGCC test provides crucial information on the presence of circulating tumor cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific types of cancer.
The Oncotrail RGCC test analyzes the markers for very specific types of cancer, including:
For instance, the breast cancer Oncotrail RGCC test will only include markers for breast cancer.
We do not use Oncotrail RGCC as a primary diagnostic test to confirm a cancer diagnosis. For this, we recommend the Oncotrace test, which is a more comprehensive tool to discover all primary and secondary cancer types.
However, once the cancer type has been identified, the Oncotrail RGCC test provides essential information on the effectiveness of current cancer treatments focused on your type of cancer. Follow-up tests can also be used to monitor your health and assess the risk of recurrence.
Let’s look at the three types of information returned by the OncoTrail test and their purpose in developing an individualized treatment plan for you.
The CTC count gives a reading of the presence of cancer cells in your bloodstream. The CTC count helps your care practitioners assess the effectiveness of the established treatment protocols. And you can see a direct correlation between the CTC count and the growth or decline in cancer cells in your body.
The Oncotrail RGCC test also provides information about phenotype markers for your cancer cells. These are tissue markers that identify the tissue where the tumor cells originate.
In this case, a marker is any mutation that distinguishes (or marks) some part of the DNA or genome. Phenotype biomarkers are defined as the expression, localization, dynamics, and modification state of DNA, RNA, and proteins connected to the cancerous tumor.
Phenotypic biomarkers are useful for:
The third type of information recorded by the Oncotrail RGCC test is data on the stem cell markers for your cancer, called the stemness markers. The stemness markers provide information on the behavior and activity level of cancer cells in the bloodstream.
If the stemness markers are in an active state (or “On” position), it shows high levels of activity of cancer cells, indicating the cancer can proliferate, metastasize, or recur.
Oncotrail RGCC results are used for comprehensive monitoring of the effectiveness of your cancer treatment plan. If your cancer has gone into remission, the Oncotrail RGCC can be an extremely effective instrument for early detection of recurrence.
Conventional monitoring treatment options can detect recurring cancer only once the tumor has grown large enough to be visible on imaging tests.
The goal of cancer treatment is to reduce the number of CTCs in the bloodstream. Once this is achieved, you may think that cancer has been eliminated. But this is only half the picture.
The additional information about the activity of the stemness markers recorded in the Oncotrail RGCC results adds crucial information about your cancer prognosis.
Therefore, the activity levels of the stemness markers give you a true indication of whether treatment needs to continue - even when the CTC count has reached a desired low number.
This means treatment protocols can start early instead of waiting for any further worsening of the situation.
As you progress with your treatment, the package of information provided by the Oncotrail RGCC test can be a powerful tool to assess how well things are going with your cancer treatment.
Once the cancer is in full remission and the first 2-3 follow-up tests show the condition as stable, the CTC tests can be taken every 6 months as part of your monitoring protocols.
Regular monitoring is vital for the early detection of recurrence and living a cancer-free life.
Our testing protocols empower you and your care team with information that tells you about what is happening with your cancer at all times.
The Oncotrail RGCC test is designed as a follow-up and monitoring test for patients who are undergoing cancer treatment or have had cancer in the past and may be worried about the disease returning.
Our accredited practitioners can use Oncotrail RGCC results to assess the effectiveness of cancer treatment and evaluate the likelihood of cancer returning.
The Oncotrail RGCC test is performed using a liquid biopsy. Patients provide us with their blood samples, and no surgery or tissue biopsy is needed. Brain and CNS cancers require a tissue or CSF sample instead of blood sample. The sample is then shipped to our laboratory in Greece for analysis.
Please note that if a patient is undergoing cancer treatment, we recommend waiting 7 to 21 days or more after chemotherapy to take the test.
All our accredited practitioners understand our shipping instructions and ensure the sample arrives in perfect condition.
To know what to expect from the test results, view a sample of one of our Oncotrail RGCC test results. Click on the link for the type of cancer to see the sample for it.
Breast | Prostate | Melanoma | Esophageal (GI) | Sarcoma | Lung | Colorectal
Price in Euros: € 775
Disclaimer:
* Prices in $USD vary slightly based on the exchange rate on the day the test is ordered.
** These prices do not include in-office fees such as consultation, blood draws, IV administration, etc.
Your sample will be processed at our state-of-the-art laboratory in Greece. Once the test is completed, we will provide a detailed breakdown of our findings. The results are sent to your accredited practitioner who downloads the results and sets up an appointment with you to go over the results.
We recommend that you also discuss the results with your cancer care team and work together to develop a personalized treatment plan based on our findings.
Our scientists use world-leading technology, equipment, and innovative techniques to develop a range of cancer screening and monitoring tests. Our tests help cancer patients and their healthcare professionals get a comprehensive but personalized view of each patient’s genetics, physiology, and immune profiles.
We believe this level of detail is crucial in developing an individualized care plan for every patient struggling with cancer. We aim to provide a unique insight into every patient’s cancer biology to empower them about what treatment options are ideal for bringing them success in their cancer journey!
Reach out to us to start your journey to empowering information today by contacting us online.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s Oncocount and Oncotrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s OncoCount and OncoTrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Read more about our therapies on our website: https://rgcc-international.com/rgcc-therapies/
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient’s genes.
Individualized treatment for cancer is the focus behind RGCC’s testing protocols and advanced therapy options. Our slate of tests analyzes the state of a person’s cancer by looking at the cellular and genetic makeup of each patient. Our test results give you information that acts as a blueprint for what treatment protocols are likely to show the most efficacy for your specific biology.
Learn more about RGCC at
https://rgcc-international.com/
Follow us on social media to find out the latest news and updates from our experts.
Facebook: https://www.facebook.com/profile.php?id=61554630098937
Instagram: https://www.instagram.com/rgcc_north_america/
LinkedIn: https://www.linkedin.com/company/r-g-c-c-international-gmbh/
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
